AU2001264747A1 - Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens - Google Patents

Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens

Info

Publication number
AU2001264747A1
AU2001264747A1 AU2001264747A AU6474701A AU2001264747A1 AU 2001264747 A1 AU2001264747 A1 AU 2001264747A1 AU 2001264747 A AU2001264747 A AU 2001264747A AU 6474701 A AU6474701 A AU 6474701A AU 2001264747 A1 AU2001264747 A1 AU 2001264747A1
Authority
AU
Australia
Prior art keywords
thehuman
identification
binding interactions
certain antibodies
unique binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264747A
Inventor
Darrell R. Anderson
Peter Brams
Nabil Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/576,424 external-priority patent/US7175847B1/en
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of AU2001264747A1 publication Critical patent/AU2001264747A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
AU2001264747A 2000-05-22 2001-05-22 Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens Abandoned AU2001264747A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09576424 2000-05-22
US09/576,424 US7175847B1 (en) 1995-06-07 2000-05-22 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
PCT/US2001/016364 WO2001089567A1 (en) 2000-05-22 2001-05-22 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens

Publications (1)

Publication Number Publication Date
AU2001264747A1 true AU2001264747A1 (en) 2001-12-03

Family

ID=24304362

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264747A Abandoned AU2001264747A1 (en) 2000-05-22 2001-05-22 Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens

Country Status (2)

Country Link
AU (1) AU2001264747A1 (en)
WO (1) WO2001089567A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002060485A2 (en) * 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US7527969B2 (en) * 2002-06-19 2009-05-05 Raven Biotechnologies, Inc. RAAG10 cell surface target and a family of antibodies recognizing that target
JP2006524036A (en) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． Single domain antibodies targeting tumor necrosis factor alpha and uses thereof
AU2003286003B2 (en) * 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
WO2004076488A1 (en) * 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
JP5601836B2 (en) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド TES7 and antibodies that bind to TES7
CA2682027A1 (en) * 2007-03-28 2008-10-02 Biogen Idec Inc. Modulation of tumor microenvironment
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
MX2020014101A (en) * 2018-06-22 2021-05-27 Junten Bio Co Ltd Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007090B1 (en) * 1996-11-08 2009-12-30 Biogen Idec Inc. Identification of unique binding interactions between certain antibodies and the human b7.1 (cd80) and b7.2 (cd28) co-stimulatory antigens

Also Published As

Publication number Publication date
WO2001089567A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
IL223047A (en) Antibody comprising an fc region and uses thereof
AU2001264747A1 (en) Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
AU7398200A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ZA9810130B (en) Tumor-specific antigens methods for their production and their use for imunization and diagnosis
AU3159499A (en) Antigen preparation and use
AU2001278011A1 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001248172A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001248171A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
ZA200107602B (en) Tuberculosis antigens and methods of use therefor.
AU2994599A (en) Active immunization against angiogenesis-associated antigens
AU757752C (en) Benzylidene pyrazolones, production and use thereof
AU2000275748A1 (en) Hla-a2.1 binding peptides and their uses
AU7572198A (en) Tumor-associated antigen
AU2001284899A1 (en) Methods and universal monoclonal antibody array
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2002221428A1 (en) Novel polypeptide human polyadenylation binding protein 20.13 and polynucleotideencoding it
AU7128098A (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
AU4021800A (en) Human sperm surface antigens
AU2001268531A1 (en) 52871, a novel human g protein coupled receptor and uses thereof
AU5632500A (en) Cancer associated antigens and uses therefor
AU1135595A (en) Saccharomyces-specific antigens and antibodies, their preparation and use
AU6227800A (en) Recombinant antibody directed against human sperm antigen